OR WAIT null SECS
Curia plans to expand the site’s commercial capabilities with this move.
Contract research and development organization (CDMO) Curia, formerly AMRI, announced plans to invest more than $35 million in commercial capacity expansions for its Rensselaer, NY facility. The Rensselaer site currently produces APIs to meet the development needs of more than 50 products.
The expansion, which is expected to be completed within 18 months, will include new vessel capacities that more than double the site’s batch-size scaling and product output.The investment will increase Curia’s ability to flexibly manufacture complex small-molecule APIs to meet arange of small to large volume requirements, according to a company press release. The site can manufacture high potency APIs and is certified by the independent SafeBridge program for potent compounds.
“Some of the life-saving products produced at Rensselaer are highly complex, including critical oncology therapeutics and novel treatments addressing unmet medical needs.” said John Ratliff, Curia CEO and chairman, in the press release. “The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency, and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”